Surrozen, Inc. ( (SRZN) ) has released its Q3 earnings. Here is a breakdown of the information Surrozen, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Surrozen, Inc. is a biotechnology company focused on discovering and developing drug candidates to modulate the Wnt pathway, primarily for tissue repair in ophthalmology. In its latest earnings report for the quarter ending September 30, 2025, Surrozen reported a significant net loss of $71.6 million, compared to a net loss of $1.4 million in the same period last year. The company generated $983,000 in revenue from research services, a decrease from $10 million in the previous year, while operating expenses rose to $11.9 million. Despite the losses, Surrozen secured $71.2 million in net proceeds from a private placement to fund its ophthalmology programs. Looking ahead, Surrozen’s management remains focused on advancing its clinical studies and securing additional capital to support its long-term business strategy.